ddp4 inhibitor and glp 1 agonist Neuroprotection by dipeptidyl-peptidase-4 inhibitors glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer's disease DPP4 in Diabetes - PMC

T.WeiL.et al (2016)

This article examines the current understanding of allulose's effects on GLP-1 activity, explores potential metabolic benefits, and provides practical guidance for patients considering allulose alongside GLP-1-based therapies

A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: randomized, placebo-controlled, double-blind clinical trial

Sawami K, Tanaka A, Node K (2022) Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists

911 Although these findings provide insight into the potential relationship between GLP-1RAs and cancer risk, all existing studies have focused on comparisons among glucose-lowering drugs (GLDs) in patients with T2D, leaving uncertainty regarding their potential role in cancer prevention in individuals with obesity regardless of diabetes status